Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU. Walz G, et al. Among authors: arns w. N Engl J Med. 2010 Aug 26;363(9):830-40. doi: 10.1056/NEJMoa1003491. Epub 2010 Jun 26. N Engl J Med. 2010. PMID: 20581392 Free article. Clinical Trial.
Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease.
Zschiedrich S, Budde K, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hoerl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Lindner TH, Faerber L, Wimmer P, Stork R, Eckardt KU, Walz G. Zschiedrich S, et al. Among authors: arns w. Nephrol Dial Transplant. 2016 Feb;31(2):284-9. doi: 10.1093/ndt/gfv077. Epub 2015 Apr 1. Nephrol Dial Transplant. 2016. PMID: 25832108
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C; ZEUS Study Investigators. Lehner F, et al. Among authors: arns w. Transpl Int. 2014 Nov;27(11):1192-204. doi: 10.1111/tri.12411. Epub 2014 Aug 20. Transpl Int. 2014. PMID: 25070687 Free article. Clinical Trial.
Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
Budde K, Zeier M, Witzke O, Arns W, Lehner F, Guba M, Jacobi J, Kliem V, Reinke P, Hauser IA, Vogt B, Stahl R, Rath T, Duerr M, Paulus EM, May C, Porstner M, Sommerer C; HERAKLES Study Group. Budde K, et al. Among authors: arns w. Nephrol Dial Transplant. 2017 Jun 1;32(6):1060-1070. doi: 10.1093/ndt/gfx075. Nephrol Dial Transplant. 2017. PMID: 28605781 Clinical Trial.
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, Wüthrich RP, Mühlfeld A, Heller K, Porstner M, Veit J, Paulus EM, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: arns w. Am J Transplant. 2015 Jan;15(1):119-28. doi: 10.1111/ajt.12952. Epub 2014 Dec 17. Am J Transplant. 2015. PMID: 25521535 Free article. Clinical Trial.
101 results